Compatibility study of tobramycin and pharmaceutical excipients using differential scanning calorimetry, FTIR, DRX, and HPLC
- 138 Downloads
Differential scanning calorimetry (DSC), isothermal stress testing–Fourier transform infrared spectroscopy (IST–FTIR), isothermal stress testing–high-performance liquid chromatography, and powder X-ray diffraction (PDRX) were used as screening techniques for assessing the compatibility of tobramycin with some currently employed ophthalmic excipients. In the first phase of the study, DSC was used as a tool to detect any interaction. The absolute value of the difference between the enthalpy of the pure tobramycin melting peak and that of its melting peak in the different analyzed mixtures was chosen as a parameter of the drug–excipient interaction degree. DSC results demonstrated that benzalkonium chloride, monobasic sodium phosphate, boric acid, edetate disodium, sodium metabisulfite, thimerosal, and potassium sorbate interact with tobramycin. Taking into account these results, it could be suggested that some of the changes observed in the IST–FTIR spectra of binary blends of tobramycin and some of the excipients would account for a possible interaction between the mixture component. In this study, PDRX did not provide much information, since only tobramycin–thimerosal interactions could be detected. DSC and IST–FTIR are suitable and simple methods for the detection of potential incompatibilities between active pharmaceutical ingredient (API) and excipients.
KeywordsCompatibility studies Tobramycin DSC IST–FTIR PDRX IST–HPLC
This work was supported by Grant 20020130100342BA from UBA to A. I. Segall.
- 1.Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J Excip Food Chem. 2010;1:3–26.Google Scholar
- 23.Silva LAD, Teixeira FV, Serpa RC, Esteves NL, dos Santos RR, Lima EM, da Cunha-Filho MSS, de Souza Araújo AA, Taveira SF, Marreto RN. Evaluation of carvedilol compatibility with lipid excipients for the development of lipid-based drug delivery systems. J Therm Anal Calorim. 2016;123:2337–44.CrossRefGoogle Scholar
- 25.Rus LM, Tomuta I, Iuga C, Maier C, Kacso I, Borodi G, Bratu I, Bojita M. Compatibility studies of indapamide/pharmaceutical excipients used in tablet preformulation. Farmacia. 2012;60:92–101.Google Scholar
- 32.The United States Pharmacopeia 38th Ed. (Spanish version) U.S. Pharmacopeial Convention, Rockville; 2015. p. 6020–21.Google Scholar
- 39.Dash AK. Tobramycin. In: Brittain H, editor. Analytical profiles of drug substances and excipients, vol. 24. San Diego: Academic Press; 1996. p. 579–613.Google Scholar
- 41.Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 654–6.Google Scholar
- 43.Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 242–4.Google Scholar
- 44.Martindale, The Complete Drug reference, 32th edn. Pharmaceutical Press, London; 1999. p. 1126.Google Scholar
- 45.Kamin W, Schwabe A, Krämer I. Inhalation solutions—which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros. 2006;5:2015–213.Google Scholar
- 47.Ferrand C, Marc F, Fritsch P, De Saint Blanquat G. Interactions of sorbic acid and sorbates with food amines: role of light, oxygen, temperature and the presence of glycerol and emulsifier. Sci Aliments. 1998;18:603–16.Google Scholar